Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 76 citing articles:

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial
Tim H. Brümmendorf, Jorge E. Cortés, Dragana Milojković, et al.
Leukemia (2022) Vol. 36, Iss. 7, pp. 1825-1833
Open Access | Times Cited: 87
Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors
Andreas Hochhaus, Massimo Breccia, Giuseppe Saglio, et al.
Leukemia (2020) Vol. 34, Iss. 6, pp. 1495-1502
Open Access | Times Cited: 86
Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology
Tienush Rassaf, Matthias Totzeck, Johannes Backs, et al.
Clinical Research in Cardiology (2020) Vol. 109, Iss. 10, pp. 1197-1222
Open Access | Times Cited: 85
Senescence and senolytics in cardiovascular disease: Promise and potential pitfalls
W. Andrew Owens, Anna Walaszczyk, Ioakim Spyridopoulos, et al.
Mechanisms of Ageing and Development (2021) Vol. 198, pp. 111540-111540
Open Access | Times Cited: 82
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee
James L. Januzzi, Joseph Garasic, Scott E. Kasner, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 47
Integrated Stress Response Potentiates Ponatinib-Induced Cardiotoxicity
Gege Yan, Zhenbo Han, Youjeong Kwon, et al.
Circulation Research (2024) Vol. 134, Iss. 5, pp. 482-501
Closed Access | Times Cited: 11
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
Andreas Hochhaus, Carlo Gambacorti‐Passerini, Camille N. Abboud, et al.
Leukemia (2020) Vol. 34, Iss. 8, pp. 2125-2137
Open Access | Times Cited: 70
Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer
Cristina Gutiérrez, Colleen McEvoy, Laveena Munshi, et al.
Critical Care Medicine (2019) Vol. 48, Iss. 1, pp. 10-21
Open Access | Times Cited: 60
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option
Jeffrey H. Lipton, Tim H. Brümmendorf, Carlo Gambacorti‐Passerini, et al.
Blood Reviews (2022) Vol. 56, pp. 100968-100968
Open Access | Times Cited: 35
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
Jorge E. Cortés, Jane F. Apperley, Daniel J. DeAngelo, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 57
Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care
Moussab Damlaj, Riad El Fakih, Shahrukh K. Hashmi
Blood Reviews (2018) Vol. 33, pp. 63-73
Closed Access | Times Cited: 50
Nobiletin Promotes Megakaryocytic Differentiation through the MAPK/ERK-Dependent EGR1 Expression and Exerts Anti-Leukemic Effects in Human Chronic Myeloid Leukemia (CML) K562 Cells
Jui-Hung Yen, Ching-Yen Lin, Chin-Hsien Chuang, et al.
Cells (2020) Vol. 9, Iss. 4, pp. 877-877
Open Access | Times Cited: 42
A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia
Hagop M. Kantarjian, Elias Jabbour, Jeffrey H. Lipton, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 5, pp. 285-297
Open Access | Times Cited: 5
Ponatinib-induced ischemic stroke in larval zebrafish for drug screening
Xiaoyu Zhu, Bo Xia, Ting Ye, et al.
European Journal of Pharmacology (2020) Vol. 889, pp. 173292-173292
Closed Access | Times Cited: 37
A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities
Zahra Nekoukar, Minoo Moghimi, Ebrahim Salehifar
Blood Research (2021) Vol. 56, Iss. 4, pp. 229-242
Open Access | Times Cited: 28
Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies
Fang Cheng, Qiling Xu, Qiang Li, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 12
Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart
Alessandra Ghigo, Pietro Ameri, Aarti Asnani, et al.
European Journal of Heart Failure (2025)
Open Access
The role of bosutinib in the treatment of chronic myeloid leukemia
Carlo Gambacorti‐Passerini, Philipp le Coutre, Rocco Piazza
Future Oncology (2019) Vol. 16, Iss. 2, pp. 4395-4408
Open Access | Times Cited: 31
Cross-Domain Text Mining to Predict Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Nidhi Mehra, Armon Varmeziar, Xinyu Chen, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4686-4686
Open Access | Times Cited: 18
The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling
Darya Zibrova, Thomas Ernst, Andreas Hochhaus, et al.
Molecular and Cellular Biochemistry (2024) Vol. 480, Iss. 3, pp. 1627-1643
Open Access | Times Cited: 3
Experience with ponatinib in paediatric patients with leukaemia
Jenna Rossoff, Van Huynh, Rachel E. Rau, et al.
British Journal of Haematology (2020) Vol. 189, Iss. 2, pp. 363-368
Open Access | Times Cited: 26
Imatinib-induced changes in the expression profile of microRNA in the plasma and heart of mice—A comparison with doxorubicin
Barbora Hanousková, Mikuláš Skála, Veronika Brynychová, et al.
Biomedicine & Pharmacotherapy (2019) Vol. 115, pp. 108883-108883
Open Access | Times Cited: 24
Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease
Darryl P. Leong, Nazanin Aghel, Christopher Hillis, et al.
Heart (2021) Vol. 107, Iss. 8, pp. 667-673
Closed Access | Times Cited: 18
Who 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
İbrahim C. Haznedaroğlu, Işınsu Kuzu, Osman İlhan
Turkish Journal of Hematology (2019)
Open Access | Times Cited: 20
Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib
Grazia Casavecchia, Maurizio Galderisi, Giuseppina Novo, et al.
Heart Failure Reviews (2020) Vol. 25, Iss. 3, pp. 447-456
Closed Access | Times Cited: 19
Page 1 - Next Page

Scroll to top